# Comparison Among Erythropoietin Stimulating Agents

> **NCT02049346** · PHASE4 · COMPLETED · sponsor: **Hamad Medical Corporation** · enrollment: 327 (actual)

## Conditions studied

- Anemia of End Stage Renal Disease

## Interventions

- **DRUG:** Epoetin alpha or beta (Epoetin group)
- **DRUG:** Darbepoetin alfa
- **DRUG:** Methoxy polyethylene glycol-epoetin beta

## Key facts

- **NCT ID:** NCT02049346
- **Lead sponsor:** Hamad Medical Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03
- **Primary completion:** 2013-04
- **Final completion:** 2013-06
- **Target enrollment:** 327 (ACTUAL)
- **Last updated:** 2017-09-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02049346

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02049346, "Comparison Among Erythropoietin Stimulating Agents". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02049346. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*